MCID: LMY004
MIFTS: 63

Leiomyosarcoma

Categories: Cancer diseases, Muscle diseases, Rare diseases

Aliases & Classifications for Leiomyosarcoma

MalaCards integrated aliases for Leiomyosarcoma:

Name: Leiomyosarcoma 12 74 52 58 54 6 43 15 17 71
Leiomyosarcomas 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1967
MeSH 43 D007890
NCIt 49 C3158
SNOMED-CT 67 443719001 51549004
MESH via Orphanet 44 D007890
ICD10 via Orphanet 33 C49.9
UMLS via Orphanet 72 C0023269
Orphanet 58 ORPHA64720
UMLS 71 C0023269

Summaries for Leiomyosarcoma

NIH Rare Diseases : 52 Leiomyosarcoma is a rare cancerous tumor that consists of smooth (involuntary) muscle cells . Leiomyosarcoma is a type of sarcoma . It spreads through the blood stream and can affect the lungs, liver, blood vessels, or any other soft tissue in the body. The exact cause of leiomyosarcoma is not known, although genetic and environmental factors appear to be involved. It is most often found in the uterus or abdomen.

MalaCards based summary : Leiomyosarcoma, also known as leiomyosarcomas, is related to inflammatory leiomyosarcoma and colon leiomyosarcoma. An important gene associated with Leiomyosarcoma is KIT (KIT Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are ERK Signaling and PI3K-Akt signaling pathway. The drugs Oxaliplatin and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include uterus, smooth muscle and liver, and related phenotypes are cellular and behavior/neurological

Disease Ontology : 12 A smooth muscle cancer that can arise almost anywhere in the body, but is most common in the uterus, abdomen, or pelvis.

Wikipedia : 74 Leiomyosarcoma, is a malignant (cancerous) smooth muscle tumor. A benign tumor originating from the same... more...

Related Diseases for Leiomyosarcoma

Diseases in the Leiomyosarcoma family:

Inflammatory Leiomyosarcoma

Diseases related to Leiomyosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 908)
# Related Disease Score Top Affiliating Genes
1 inflammatory leiomyosarcoma 34.6 MYOG DES
2 colon leiomyosarcoma 34.6 WT1 PDGFRA KIT
3 uterus leiomyosarcoma 34.5 PGR MYOG KIT ENO2
4 liver leiomyosarcoma 34.5 WT1 KIT ENO2
5 gastric leiomyosarcoma 34.4 PDGFRA KIT
6 gallbladder leiomyosarcoma 34.4 MB KIT
7 breast leiomyosarcoma 34.2 MB KIT ENO2
8 cutaneous leiomyosarcoma 34.2 VIM MUC1 FH DES ACTC1
9 small intestine leiomyosarcoma 34.1 KIT IGF2
10 epithelioid leiomyosarcoma 33.8 VIM SERPINA3 PGR MUC1 MB ENO2
11 vascular cancer 32.4 SERPINA3 PDGFRB MYOG KIT
12 rare tumor 32.3 KIT DES ACTC1
13 uterine sarcoma 31.6 WT1 KIT
14 malignant fibrous histiocytoma 31.6 VIM SERPINA3 PDGFRB MYOG MUC1 MDM2
15 myoma 31.6 PGR KIT FH
16 gastrointestinal stromal tumor 31.5 WT1 VIM S100A1 PDGFRB PDGFRA KIT
17 familial retinoblastoma 31.3 RB1 MDM2 CDK4
18 bizarre leiomyoma 31.3 PGR FH ACTC1
19 fibrosarcoma 31.3 VIM PDGFRA KIT DES ACTC1
20 intravenous leiomyomatosis 31.2 PGR DES
21 meningioma, radiation-induced 31.2 VIM PGR MUC1
22 chondroma 31.2 S100A1 PDGFRA KIT ACTC1
23 secretory meningioma 31.2 VIM SERPINA3 MUC1
24 mesenchymal cell neoplasm 31.1 SERPINA3 PDGFRB PDGFRA MYOG KIT
25 spindle cell sarcoma 31.0 VIM SERPINA3 MYOG MUC1 MDM2 DES
26 leiomyomatosis 31.0 WT1 PGR KIT FH
27 endometrial adenocarcinoma 31.0 VIM PGR MUC1
28 bilateral retinoblastoma 31.0 RB1 MYOG MB DES
29 malignant mesenchymoma 31.0 SERPINA3 MYOG MDM2 MB DES
30 fibroma 30.9 VIM SERPINA3 S100A1 DES ACTC1
31 fibrous histiocytoma 30.9 VIM SERPINA3 MYOG KIT ENO2 DES
32 pneumothorax 30.9 VIM PGR MUC1 ACTC1
33 gastric leiomyoma 30.8 PDGFRA KIT FH
34 teratoma 30.8 VIM KIT ENO2 ACTC1
35 heart sarcoma 30.8 MYOG MDM2 KIT
36 sarcomatoid renal cell carcinoma 30.8 S100A1 MUC1 KIT
37 leiomyoma 30.8 VIM S100A1 PGR PDGFRA KIT IGF2
38 benign metastasizing leiomyoma 30.7 VIM PGR DES ACTC1
39 angiosarcoma 30.7 VIM MYOG MUC1 MDM2 KIT
40 pleomorphic lipoma 30.7 SERPINA3 PGR MDM2 CDK4
41 angiomyolipoma 30.7 VIM S100A1 PGR KIT DES ACTC1
42 vagina sarcoma 30.7 VIM PGR MYOG KIT
43 neurofibroma 30.6 VIM S100A1 PDGFRA MUC1 KIT ACTC1
44 liposarcoma 30.6 VIM RB1 PDGFRA MYOG MDM2 MB
45 lipomatosis, multiple 30.6 SERPINA3 MDM2 KIT DES CDK4
46 smooth muscle tumor 30.6 VIM SERPINA3 S100A1 PGR KIT IGF2
47 spindle cell carcinoma 30.6 VIM PGR MUC1 ENO2 DES ACTC1
48 bladder sarcoma 30.6 SERPINA3 MYOG
49 retroperitoneal sarcoma 30.6 MYOG MDM2 KIT CDK4
50 myoepithelioma 30.6 VIM S100A1 MUC1 ACTC1

Graphical network of the top 20 diseases related to Leiomyosarcoma:



Diseases related to Leiomyosarcoma

Symptoms & Phenotypes for Leiomyosarcoma

MGI Mouse Phenotypes related to Leiomyosarcoma:

45 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.51 ACTC1 CDK4 DES ENO2 FH IGF2
2 behavior/neurological MP:0005386 10.44 CDK4 DES ENO2 IGF2 KIT MDM2
3 cardiovascular system MP:0005385 10.43 ACTC1 CDK4 DES IGF2 KIT MB
4 homeostasis/metabolism MP:0005376 10.42 ACTC1 CDK4 DES FH IGF2 KIT
5 growth/size/body region MP:0005378 10.34 ACTC1 CAPN6 CDK4 ENO2 IGF2 KIT
6 embryo MP:0005380 10.33 CDK4 IGF2 KIT MB MDM2 MYOG
7 mortality/aging MP:0010768 10.31 ACTC1 CDK4 DES FH IGF2 KIT
8 muscle MP:0005369 10.31 ACTC1 CAPN6 CDK4 DES IGF2 KIT
9 hematopoietic system MP:0005397 10.25 CDK4 IGF2 KIT MB MDM2 PDGFRA
10 craniofacial MP:0005382 10.22 CAPN6 CDK4 ENO2 IGF2 KIT MDM2
11 endocrine/exocrine gland MP:0005379 10.19 CDK4 IGF2 KIT MDM2 PDGFRA PDGFRB
12 integument MP:0010771 10.18 CDK4 IGF2 KIT MDM2 MYOG PDGFRA
13 digestive/alimentary MP:0005381 10.16 CAPN6 CDK4 IGF2 KIT MDM2 PDGFRA
14 limbs/digits/tail MP:0005371 10 IGF2 KIT MDM2 PDGFRA PDGFRB PGR
15 normal MP:0002873 10 ACTC1 CDK4 KIT MDM2 MYOG PDGFRA
16 no phenotypic analysis MP:0003012 9.92 IGF2 KIT MDM2 MYOG PDGFRA PGR
17 neoplasm MP:0002006 9.91 CDK4 KIT MDM2 PDGFRA PGR RB1
18 renal/urinary system MP:0005367 9.81 CDK4 FH IGF2 KIT MDM2 PDGFRA
19 reproductive system MP:0005389 9.65 CDK4 IGF2 KIT MDM2 PDGFRA PDGFRB
20 respiratory system MP:0005388 9.32 ENO2 IGF2 KIT MB MYOG PDGFRA

Drugs & Therapeutics for Leiomyosarcoma

Drugs for Leiomyosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 177)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4 61825-94-3 43805 6857599 5310940 9887054
2
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
3
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
4
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
5
Ondansetron Approved Phase 3 99614-02-5 4595
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
7
Etoposide Approved Phase 3 33419-42-0 36462
8
Epirubicin Approved Phase 3 56420-45-2 41867
9 Olaratumab Approved, Investigational Phase 3 1024603-93-7
10
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
11
Ifosfamide Approved Phase 2, Phase 3 3778-73-2 3690
12
Mechlorethamine Approved, Investigational Phase 2, Phase 3 51-75-2 4033
13
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
14
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166
15
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
16
Gemcitabine Approved Phase 3 95058-81-4 60750
17
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
18
Lenograstim Approved, Investigational Phase 3 135968-09-1
19
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
20
Bevacizumab Approved, Investigational Phase 3 216974-75-3
21
Histamine Approved, Investigational Phase 3 51-45-6 774
22
Cyproheptadine Approved Phase 3 129-03-3 2913
23 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
24 Molgramostim Investigational Phase 3 99283-10-0
25 Anti-Bacterial Agents Phase 3
26 Anti-Infective Agents Phase 3
27 Antirheumatic Agents Phase 3
28 Hormone Antagonists Phase 3
29 Hormones Phase 3
30 Antineoplastic Agents, Hormonal Phase 3
31 Antiemetics Phase 3
32 glucocorticoids Phase 3
33 Anti-Inflammatory Agents Phase 3
34 Cola Phase 3
35 Analgesics Phase 3
36 Liver Extracts Phase 3
37 Anti-Anxiety Agents Phase 3
38 Psychotropic Drugs Phase 3
39 Antipsychotic Agents Phase 3
40 Anesthetics Phase 3
41 Narcotics Phase 3
42 Analgesics, Opioid Phase 3
43 Anesthetics, General Phase 3
44 Anesthetics, Intravenous Phase 3
45 Etoposide phosphate Phase 3
46
Isophosphamide mustard Phase 2, Phase 3 0
47
Liposomal doxorubicin Phase 2, Phase 3 31703
48 Antibiotics, Antitubercular Phase 3
49 Immunologic Factors Phase 3
50 Antiviral Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 195)
# Name Status NCT ID Phase Drugs
1 Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin Unknown status NCT00274885 Phase 4 oxaliplatin
2 Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule Recruiting NCT04223583 Phase 4 Anlotinib Hydrochloride
3 A Phase III Randomized Study of Preoperative Radiotherapy Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcoma (RPS) Unknown status NCT01344018 Phase 3
4 Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
5 Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age Unknown status NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
6 A Randomized Controlled Study of YONDELIS (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Completed NCT01343277 Phase 3 Trabectedin;Dacarbazine
7 Multicenter, Open-label Study of YONDELIS (Trabectedin) in Subjects With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Completed NCT01692678 Phase 3 Trabectedin;Dacarbazine
8 Phase III Randomized Study of Adjuvant Pelvic Radiotherapy Versus Observation Alone in Patients With Completely Resected, Stage I or II, High-Grade Uterine Sarcoma Completed NCT00002459 Phase 3
9 Randomized Phase III Trial of Two Investigational Schedules of Ifosfamide vs. Standard Dose Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
10 METASTASECTOMY AND CHEMOTHERAPY FOR LUNG METASTASES FROM SOFT TISSUE SARCOMA: A RANDOMIZED PHASE III STUDY (AN INTERGROUP STUDY WITH THE SCANDINAVIAN SARCOMA GROUP) Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
11 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
12 Randomised Trial of Post-Operative Radiotherapy Given to Adult Patients With Extremity Soft Tissue Sarcoma [VORTEX] Completed NCT00423618 Phase 3
13 A Phase III Randomized Study of Preoperative Radiation Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcomas (RPS) Completed NCT00091351 Phase 3
14 Randomized Study Comparing Neoadjuvant Chemotherapy Etoposide + Ifosfamide + Adriamycin (EIA) Combined With Regional Hyperthermia (RHT) Versus Neoadjuvant Chemotherapy Alone in the Treatment of High-Risk Soft Tissue Sarcomas in Adults Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
15 Randomised Trial Of Single Agent Doxorubicin Versus Doxorubicin Plus Ifosfamide In The First Line Treatment Of Advanced Or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
16 A Randomized Phase III Double-Blind Study Of Ondansetron And Dexamethasone Versus Ondansetron And Placebo In The Prophylaxis Of Radiation-Induced Emesis Completed NCT00016380 Phase 3 dexamethasone;ondansetron
17 MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
18 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
19 A Phase III Study of AL3818 (Anlotinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma Recruiting NCT03016819 Phase 3 AL 3818;Dacarbazine
20 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
21 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting NCT02451943 Phase 3 Olaratumab;Doxorubicin;Placebo
22 Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754) Active, not recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride
23 Randomised Phase III Multicentric Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin in Non-progressive Patients Versus Doxorubicine Alone as First-line Therapy in Patients With Metastatic or Unresectable Leiomyosarcoma (Uterine or Soft Tissue) Not yet recruiting NCT02997358 Phase 3 Doxorubicin;Trabectedin
24 A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients With High Risk RetroPeritoneal Sarcoma (RPS) Not yet recruiting NCT04031677 Phase 3 Preoperative chemotherapy
25 Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Grade 1 or 2 Soft Tissue Sarcoma Not yet recruiting NCT04307277 Phase 3 Standard of care + chemotherapy
26 A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) Versus Observation for Uterus-Limited, High Grade Uterine Leiomyosarcoma Terminated NCT01533207 Phase 3 Docetaxel;Doxorubicin Hydrochloride;Gemcitabine Hydrochloride
27 A Randomized Phase III Evaluation of Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF With Bevacizumab (NSC #704865) Versus Docetaxel (NSC #628503) and Gemcitabine (NSC #613327) Plus G-CSF With Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus Terminated NCT01012297 Phase 3 Docetaxel;Gemcitabine Hydrochloride
28 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
29 TRUSTS: A Phase IIB/III Multicenter Study Comparing the Efficacy of TRabectedin Administered as a 3-Hour or 24-Hour Infusion to Doxorubicin in Patients With Advanced or Metastatic Untreated Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
30 Time to Secondary Resistance to Trabectedin After Interruption Versus Continuation in Responding Patients With Liposarcoma, Leiomyosarcoma and Synovial Sarcoma Withdrawn NCT03773510 Phase 3 Trabectedin discontinuation;Trabectedin continuation
31 GEIS-27: Phase I/II Multicenter and Prospective Trial of Nilotinib and Adriamycin as Neoadjuvant Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum Unknown status NCT02587169 Phase 1, Phase 2 Nilotinib-adriamycin
32 A Clinicopathological Phase II Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas Unknown status NCT01140737 Phase 2 Axitinib
33 A Phase II Study of Combination Therapy of a Protracted Oral Schedule of Temozolomide and Thalidomide as First-Line or Subsequent Therapy for Patients With Metastatic, Locally Advanced or Unresectable Leiomyosarcoma Unknown status NCT00033709 Phase 2 temozolomide;thalidomide
34 Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
35 Phase II Evaluation of Temodal (Temozolomide, Schering) in Previously Treated Advanced Sarcomas Unknown status NCT00003718 Phase 2 temozolomide
36 Activity and Safety of Regorafenib in Patients With Metastatic Soft Tissue Sarcoma Previously Treated With Anthracycline-based Chemotherapy : a Multinational, Randomized, Phase II, Placebo-controlled Trial Unknown status NCT01900743 Phase 2 Regorafenib;Placebo
37 A Multicentric Phase II Trial Studying Efficacy of Doxorubicin Associated With Trabectedin (Yondelis) in First Line Treatment on Patients With Metastatic Leiomyosarcoma (Uterus or Soft Tissue) and/or Inoperable Relapse Completed NCT02131480 Phase 2 Doxorubicin;Trabectedin
38 A Phase II Randomized - Non Comparative - Study on the Activity of Trabectedin or Gemcitabine + Docetaxel in Metastatic or Locally Relapsed Uterine Leiomyosarcoma Pretreated With Conventional Chemotherapy Completed NCT02249702 Phase 2 gemcitabine + docetaxel;trabectedin
39 Phase II Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) in Patients With Soft-Tissue Sarcomas Completed NCT00005874 Phase 2 rubitecan
40 A Phase II Evaluation of Trabectedin (Yondelis, R279741) in the Treatment of Advanced, Persistent, or Recurrent Uterine Leiomyosarcomas Completed NCT00379145 Phase 2 trabectedin
41 Phase II Multicenter Study to Determine the Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patients With Metastatic or Relapsed Uterine or Soft Tissue Leiomyosarcomas Completed NCT01442662 Phase 2 pazopanib + gemcitabine
42 A Phase II Study on Trabectedin in Advanced Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma Completed NCT02247544 Phase 2 Trabectedin
43 Randomized Phase II Study Evaluating the Efficacy of Gemcitabine Versus the Gemcitabine/Docetaxel Combination as Second Line Treatment in Metastatic or Relapsed and Inoperable Uterine or Soft Tissue Leiomyosarcomas Completed NCT00227669 Phase 2 docetaxel;gemcitabine hydrochloride
44 A Phase 2 Multi Center Open Label Study of ARQ 501 in Adult Patients With Recurrent, Persistent or Metastatic Leiomyosarcoma Completed NCT00310518 Phase 2 ARQ 501
45 A Phase II Study of AP23573, An mTOR Inhibitor, in Patients With Advanced Sarcoma Completed NCT00093080 Phase 2 ridaforolimus
46 A Phase II Trial of Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma Completed NCT00004066 Phase 2 docetaxel;gemcitabine hydrochloride
47 Adjuvant Treatment of High Risk Uterine Leiomyosarcoma With Gemcitabine/Docetaxel Followed by Doxorubicin: A Phase II Trial Completed NCT00282087 Phase 2 gemcitabine, docetaxel, doxorubicin
48 A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT01637961 Phase 2 Alisertib
49 A Phase II Study of Mocetinostat Administered With Gemcitabine for Patients With Metastatic Leiomyosarcoma With Progression or Relapse Following Prior Treatment With Gemcitabine-Containing Therapy Completed NCT02303262 Phase 2 Mocetinostat;Gemcitabine
50 A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT01220609 Phase 2 Ixabepilone

Search NIH Clinical Center for Leiomyosarcoma

Cochrane evidence based reviews: leiomyosarcoma

Genetic Tests for Leiomyosarcoma

Anatomical Context for Leiomyosarcoma

MalaCards organs/tissues related to Leiomyosarcoma:

40
Uterus, Smooth Muscle, Liver, Bone, Lung, Breast, Small Intestine

Publications for Leiomyosarcoma

Articles related to Leiomyosarcoma:

(show top 50) (show all 10043)
# Title Authors PMID Year
1
Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors. 61 54
20081808 2010
2
Expression of Ki-67, P53 and progesterone receptors in uterine smooth muscle tumors. Diagnostic value. 61 54
20437637 2010
3
WT-1 expression in gastrointestinal stromal tumours. 54 61
20025481 2010
4
Axillary and perianal leiomyosarcoma: report of two cases. 61 54
20495760 2010
5
A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors. 54 61
19734847 2009
6
Gastric leiomyosarcoma manifesting peculiar findings: radiological-pathological correlation. 61 54
19432672 2009
7
[Acute abdomen for perforated gastrointestinal stromal tumor (GIST). A case report]. 61 54
19537128 2009
8
Utility of a comprehensive immunohistochemical panel in the differential diagnosis of spindle cell lesions of the urinary bladder. 54 61
18941404 2009
9
Absence of fumarate hydratase mutation in a family with cutaneous leiomyosarcoma and renal cancer. 54 61
18986479 2008
10
Selective progesterone receptor modulators 3: use in oncology, endocrinology and psychiatry. 61 54
18778186 2008
11
[Immunohistochemical study of endometrial stromal sarcoma and smooth-muscle tumors of the uterus]. 54 61
18565690 2008
12
Clinicopathological characteristics of gastrointestinal mesenchymal tumors and diagnostic value of endoscopic ultrasonography. 54 61
18505417 2008
13
Recurrent nodule on the nasal columella: a good reason to re-biopsy. 61 54
18613884 2008
14
Cytoplasmic overexpression of WT-1 in gastrointestinal stromal tumor and other soft tissue tumors. 61 54
18528287 2008
15
Breast metastasis from uterine leiomyosarcoma diagnosed by fine needle aspiration: a case report. 61 54
18702371 2008
16
Immunohistochemical distinction of cutaneous spindle cell carcinoma. 61 54
18496422 2008
17
A rare tumor in the adrenal region: neuron-specific enolase (NSE)-producing leiomyosarcoma in an elderly hypertensive patient. 61 54
18250540 2008
18
[Adult prostate sarcoma: a report of 6 cases with clinical analysis]. 54 61
17725305 2007
19
Expression of cyclooxygenase-2, c-kit, progesterone and estrogen receptors in uterine smooth muscle tumors: differential diagnosis. 61 54
17550381 2007
20
Expression of chemokines CCL5 and CCL11 by smooth muscle tumor cells of the uterus and its possible role in the recruitment of mast cells. 61 54
17368523 2007
21
Utility of ALK-1 protein expression and ALK rearrangements in distinguishing inflammatory myofibroblastic tumor from malignant spindle cell lesions of the urinary bladder. 61 54
17396140 2007
22
Comparative study using rabbit-derived polyclonal, mouse-derived monoclonal, and rabbit-derived monoclonal antibodies for KIT immunostaining in GIST and other tumors. 54 61
17316415 2007
23
C-kit protein expression in uterine and ovarian mesenchymal tumours. 61 54
17367465 2007
24
PDGFR-alpha as a potential therapeutic target in uterine sarcomas. 61 54
17049587 2007
25
Esophageal mesenchymal tumors: endoscopy, pathology and immunohistochemistry. 61 54
17278201 2007
26
Nestin expression as a new marker in malignant peripheral nerve sheath tumors. 54 61
17300669 2007
27
[Gastrointestinal mesenchymal tumors: a clinical pathologic and immunohistochemical study of 210 cases]. 61 54
17253165 2007
28
Expression of the O-linked N-acetylglucosamine containing epitope H in normal myometrium and uterine smooth muscle cell tumors. 61 54
17129677 2007
29
Increased expression of calpain 6 in uterine sarcomas and carcinosarcomas: an immunohistochemical analysis. 54 61
17291261 2007
30
A case of cutaneous leiomyosarcoma with overexpression of KIT: do CD117 (KIT)-positive primary gastrointestinal stromal tumours of the skin exist? 61 54
16634920 2006
31
Gastrointestinal stromal tumors: differential diagnosis. 61 54
17193824 2006
32
No evidence for epigenetic inactivation of fumarate hydratase in leiomyomas and leiomyosarcomas. 61 54
15949892 2006
33
[Extragastrointestinal stromal tumors: a report of 4 cases]. 54 61
16472759 2006
34
Mammary NOS-type sarcoma with CD10 expression: a rare entity with features of myoepithelial differentiation. 54 61
16625090 2006
35
Calretinin expression in tumors of adipose tissue. 54 61
16613326 2006
36
Analysis of allelic loss as an adjuvant tool in evaluation of malignancy in uterine smooth muscle tumors. 54 61
16330948 2006
37
Inflammatory myofibroblastic tumor of the uterus: a clinicopathologic study of 6 cases emphasizing distinction from aggressive mesenchymal tumors. 54 61
16160478 2005
38
The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study. 61 54
15992918 2005
39
KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. 54 61
16082245 2005
40
Primary osteosarcoma of the thoracic spine: report of an unusual elderly patient with autopsy findings. 54 61
15753962 2005
41
INI1 expression is retained in composite rhabdoid tumors, including rhabdoid meningiomas. 61 54
15761491 2005
42
Carcinosarcoma of the liver: a case report and review of the literature. 61 54
15913431 2005
43
Imatinib mesylate (gleevec)--targeted kinases are expressed in uterine sarcomas. 54 61
15894930 2005
44
Smooth muscle tumours of the uterine corpus: a clinicopathologic study with immunohistochemical aspects. 61 54
16033061 2005
45
So-called "inflammatory leiomyosarcoma'': a series of 3 cases providing additional insights into a rare entity. 61 54
15864383 2005
46
[Malignant fibrous histiocytoma: pleomorphic sarcoma NOS or pleomorphic fibrosarcoma]. 61 54
15702318 2005
47
[Morphology and immunohistochemical characteristics of hepatic primary and metastatic malignant spindle cell tumors]. 54 61
15774214 2005
48
[Gastrointestinal stromal tumor: a clinicopathological study of 74 cases]. 54 61
15796874 2005
49
Intimal sarcoma of the pulmonary artery: report of an autopsy case. 54 61
16136754 2005
50
ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder. 61 54
15577680 2004

Variations for Leiomyosarcoma

ClinVar genetic disease variations for Leiomyosarcoma:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 CHEK2 NM_007194.4(CHEK2):c.1100del (p.Thr367fs)deletion Conflicting interpretations of pathogenicity 128042 rs555607708 22:29091857-29091857 22:28695869-28695869

Cosmic variations for Leiomyosarcoma:

9 (show top 50) (show all 2128)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM149325379 ZFHX3 soft tissue,smooth muscle,leiomyosarcoma,NS c.2513A>G p.N838S 16:72957633-72957633 3
2 COSM101976974 XPO1 soft tissue,smooth muscle,leiomyosarcoma,NS c.782G>A p.R261Q 2:61496985-61496985 3
3 COSM85719005 TSC1 soft tissue,smooth muscle,leiomyosarcoma,NS c.1079C>A p.T360N 9:132911064-132911064 3
4 COSM87912584 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.376-1G>A p.? 17:7675237-7675237 3
5 COSM87903333 TP53 soft tissue,liver,sarcoma,NS c.646G>A p.V216M 17:7674885-7674885 3
6 COSM87921270 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.673-1G>T p.? 17:7674291-7674291 3
7 COSM87898818 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.916C>T p.R306* 17:7673704-7673704 3
8 COSM87901856 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.746G>T p.R249M 17:7674217-7674217 3
9 COSM87916345 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.517G>C p.V173L 17:7675095-7675095 3
10 COSM87899887 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.856G>A p.E286K 17:7673764-7673764 3
11 COSM87910722 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.764T>G p.I255S 17:7674199-7674199 3
12 COSM87922049 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.713G>T p.C238F 17:7674250-7674250 3
13 COSM87922564 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.452C>A p.P151H 17:7675160-7675160 3
14 COSM87899463 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.581T>C p.L194P 17:7674950-7674950 3
15 COSM87897883 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.659A>G p.Y220C 17:7674872-7674872 3
16 COSM87913887 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.376-2A>T p.? 17:7675238-7675238 3
17 COSM87907695 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.518T>C p.V173A 17:7675094-7675094 3
18 COSM87898351 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.743G>A p.R248Q 17:7674220-7674220 3
19 COSM88016839 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.955A>T p.K319* 17:7673573-7673573 3
20 COSM87999235 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.647T>C p.V216A 17:7674884-7674884 3
21 COSM87900303 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.638G>A p.R213Q 17:7674893-7674893 3
22 COSM87898836 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.560-1G>A p.? 17:7674972-7674972 3
23 COSM87952881 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.994-1G>C p.? 17:7670716-7670716 3
24 COSM87922945 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.394A>C p.K132Q 17:7675218-7675218 3
25 COSM87898709 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.742C>T p.R248W 17:7674221-7674221 3
26 COSM87906877 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.493C>T p.Q165* 17:7675119-7675119 3
27 COSM87918646 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.712T>A p.C238S 17:7674251-7674251 3
28 COSM87906483 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.785G>T p.G262V 17:7673835-7673835 3
29 COSM87917769 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.808T>G p.F270V 17:7673812-7673812 3
30 COSM88000514 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.976G>A p.E326K 17:7673552-7673552 3
31 COSM87900273 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.427G>A p.V143M 17:7675185-7675185 3
32 COSM87940273 TP53 soft tissue,smooth muscle,leiomyoma,NS c.734G>C p.G245A 17:7674229-7674229 3
33 COSM87908034 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.473G>A p.R158H 17:7675139-7675139 3
34 COSM87906185 TP53 soft tissue,smooth muscle,leiomyoma,NS c.517G>T p.V173L 17:7675095-7675095 3
35 COSM87924187 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.595G>T p.G199* 17:7674936-7674936 3
36 COSM87897745 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.524G>A p.R175H 17:7675088-7675088 3
37 COSM87967575 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.631A>G p.T211A 17:7674900-7674900 3
38 COSM87975568 TP53 soft tissue,liver,sarcoma,NS c.359A>T p.K120M 17:7676010-7676010 3
39 COSM87898714 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.844C>T p.R282W 17:7673776-7673776 3
40 COSM87898527 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.814G>A p.V272M 17:7673806-7673806 3
41 COSM87900348 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.1010G>T p.R337L 17:7670699-7670699 3
42 COSM87907134 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.97-2A>T p.? 17:7676274-7676274 3
43 COSM87899497 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.586C>T p.R196* 17:7674945-7674945 3
44 COSM87901548 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.374C>A p.T125K 17:7675995-7675995 3
45 COSM87905185 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.841G>C p.D281H 17:7673779-7673779 3
46 COSM87934286 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.641A>C p.H214P 17:7674890-7674890 3
47 COSM87912393 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.577C>T p.H193Y 17:7674954-7674954 3
48 COSM87919221 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.844C>G p.R282G 17:7673776-7673776 3
49 COSM87907064 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.473G>C p.R158P 17:7675139-7675139 3
50 COSM88168858 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.753C>G p.I251M 17:7674210-7674210 3

Copy number variations for Leiomyosarcoma from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 102985 16 58400001 69400000 Loss Leiomyosarcoma

Expression for Leiomyosarcoma

Search GEO for disease gene expression data for Leiomyosarcoma.

Pathways for Leiomyosarcoma

Pathways related to Leiomyosarcoma according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.6 VIM RB1 PDGFRB PDGFRA MUC1 MDM2
2
Show member pathways
12.64 RB1 PDGFRB PDGFRA MDM2 KIT IGF2
3
Show member pathways
12.63 RB1 PDGFRB PDGFRA MDM2 KIT CDK4
4
Show member pathways
12.61 RB1 PGR KIT IGF2 CDK4
5
Show member pathways
12.52 RB1 PDGFRB PDGFRA MDM2 CDK4
6
Show member pathways
12.31 PDGFRB PDGFRA MDM2 CAPN6
7 12.28 RB1 PDGFRB PDGFRA MDM2 KIT IGF2
8
Show member pathways
12.08 RB1 PDGFRB PDGFRA KIT IGF2
9
Show member pathways
12.04 RB1 PDGFRB PDGFRA MDM2 CDK4
10 11.7 RB1 MDM2 CDK4
11 11.61 RB1 MDM2 CDK4
12 11.59 VIM DES ACTC1
13 11.56 PDGFRB PDGFRA KIT
14
Show member pathways
11.4 PDGFRB PDGFRA KIT
15 11.33 RB1 MDM2 CDK4
16 11.18 PDGFRA KIT IGF2 ACTC1
17 11.15 RB1 PDGFRB PDGFRA MDM2 IGF2 CDK4
18
Show member pathways
11.03 PDGFRB PDGFRA KIT
19 10.75 VIM PDGFRB PDGFRA KIT IGF2 DES

GO Terms for Leiomyosarcoma

Cellular components related to Leiomyosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.8 WT1 VIM SERPINA3 S100A1 RB1 PGR
2 cytoplasm GO:0005737 9.5 WT1 VIM S100A1 PGR PDGFRB PDGFRA

Biological processes related to Leiomyosarcoma according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.97 WT1 VIM MDM2 KIT ACTC1
2 positive regulation of cell proliferation GO:0008284 9.88 PDGFRB PDGFRA MDM2 KIT IGF2 CDK4
3 positive regulation of protein kinase B signaling GO:0051897 9.81 PDGFRB PDGFRA KIT IGF2
4 cell chemotaxis GO:0060326 9.76 PDGFRB PDGFRA KIT
5 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.75 PDGFRB PDGFRA KIT
6 positive regulation of kinase activity GO:0033674 9.73 PDGFRB PDGFRA KIT
7 hematopoietic progenitor cell differentiation GO:0002244 9.72 PDGFRB PDGFRA KIT
8 positive regulation of fibroblast proliferation GO:0048146 9.67 PDGFRB PDGFRA CDK4
9 muscle filament sliding GO:0030049 9.61 VIM DES ACTC1
10 metanephric mesenchyme development GO:0072075 9.54 WT1 PDGFRB
11 retina vasculature development in camera-type eye GO:0061298 9.52 PDGFRB PDGFRA
12 metanephric S-shaped body morphogenesis GO:0072284 9.48 WT1 PDGFRB
13 enucleate erythrocyte differentiation GO:0043353 9.46 RB1 MB
14 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.43 PDGFRB PDGFRA KIT
15 metanephric glomerular capillary formation GO:0072277 9.37 PDGFRB PDGFRA
16 adrenal gland development GO:0030325 9.33 WT1 PDGFRB PDGFRA
17 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.32 PDGFRB PDGFRA
18 cardiac myofibril assembly GO:0055003 9.13 PDGFRB PDGFRA ACTC1
19 positive regulation of phospholipase C activity GO:0010863 8.8 PDGFRB PDGFRA KIT

Molecular functions related to Leiomyosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet-derived growth factor binding GO:0048407 9.26 PDGFRB PDGFRA
2 vascular endothelial growth factor binding GO:0038085 9.16 PDGFRB PDGFRA
3 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 PDGFRB PDGFRA KIT
4 growth factor binding GO:0019838 8.8 PDGFRB PDGFRA KIT

Sources for Leiomyosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....